Results 91 to 100 of about 6,946 (216)
Dermatologic Therapy, Volume 2026, Issue 1, 2026.Introduction Minoxidil is a primary treatment for male androgenetic alopecia (AGA), but its slow onset and limited effectiveness, especially in restoring the frontal hairline in basic M‐type AGA, often result in poor adherence. We investigated whether combining minoxidil with ablative fractional CO2 laser, which enhances transdermal absorption and the ...
Xu Zhao +9 more
wiley +1 more source
Jurnal Urologi Indonesia, 2018 Objective: To evaluate the success rates of tamsulosin and dutasteride as medical therapy based on international prostate symptom score (IPSS) in symptomatic benign prostatic hyperplasia (BPH) patients. Materials & Methods: We reviewed medical records of
Zuhirman Zamzami
doaj +1 more source
Add-on Effect of Dutasteride in Patients With Benign Prostatic Hyperplasia Treated With Alpha Blocker : Its Effect on Overactive Bladder [PDF]
, 2012 We investigated the add-on effect of dutasteride (0.5 mg once a day) on lower urinary tract symptoms (LUTS), prostate volume (PV), and serum prostate specific antigen (PSA) and testosterone level in 72 patients with benign prostatic hyperplasia (BPH) who
北, 雅史 +6 more
core
International Journal of Science and Engineering, 2015 Objectives: to find the efficacy dutasteride and green tea in reducing hemorrhage on TURP patients and to evaluate the anti- angiogenesis effect. Methods: Double Blind Randomized Controlled Trial Post Test Only, with 80 samples, randomized into 4 ...
Eriawan Agung Nugroho +3 more
doaj +1 more source
Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. [PDF]
, 2018 Prostate cancer (PCa) is a leading cause of mortality and morbidity globally. While genomic alterations have been identified in PCa, in contrast to some other cancers, use of such information to personalize treatment is still in its infancy.
Dorff, Tanya +6 more
core +3 more sources
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. [PDF]
, 2008 BackgroundPrevious studies of drug trials submitted to regulatory authorities have documented selective reporting of both entire trials and favorable results.
Bacchetti, Peter +2 more
core +3 more sources
International Journal of Nanomedicine, 2013 Min-Soo KimDepartment of Pharmaceutical Engineering, Inje University, Gimhae, Gyeongnam, Republic of KoreaAbstract: The objectives of this study were to develop a novel solid dutasteride formulation with improved physicochemical properties and oral ...
Kim MS
doaj
Jurnal Urologi Indonesia, 2016 Objective: To compare the IPSS, Q max, and volume of the prostate pre and post treatment of 5α-reductase inhibitor and tamoxyfen in patients with BPH. Material and Methods: We collected 40 patients who had been diagnosed as BPH without urine retention ...
Kurnia Penta Seputra +2 more
doaj +1 more source
The Aging MaleBackground Dutasteride is used to treat voiding symptoms; its impact on storage symptoms is unclear.Methods We reviewed 8122 men in the placebo and dutasteride arms from the REDUCE trial.
Alexander Hernandez-Tirado +5 more
doaj +1 more source
Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. [PDF]
, 2015 The global cancer burden continues to rise and the war on cancer can only be won if improvements in treatment go hand in hand with therapeutic cancer prevention.
Bonanni, B +4 more
core +2 more sources